Edgewise Therapeutics has presented long-term data from the MESA study of sevasemten, an investigational treatment for Becker muscular dystrophy, at …
Edgewise Therapeutics Announces Long-Term Sevasemten Data in Becker Muscular DystrophyRead More
European Medicines Agency Issues Positive Opinion on Givinostat
On the 25th of April, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) gave Givinostat (Duvyzat) a …
European Medicines Agency Issues Positive Opinion on GivinostatRead More
Capricor Therapeutics Reports Positive Long-Term Results for Deramiocel in Treating Duchenne Muscular Dystrophy
This week Capricor Therapeutics announced positive long-term data from its' ongoing HOPE-2 open-label extension (OLE) clinical trial, highlighting the …
Edgewise-funded natural history trial of Becker Muscular Dystrophy (BMD) now enrolling
Edgewise Therapeutics has announced the start of an observational trial in participants with Becker Muscular Dystrophy (‘BMD’)) as assessed by …
Edgewise-funded natural history trial of Becker Muscular Dystrophy (BMD) now enrollingRead More
TREAT-NMD Statement on Stem Cell Tourism
We receive many questions from families who are interested in stem cell therapy as a potential treatment for Duchenne. Today, Treat-NMD (an …
Project that aimed to combine stem cell and CRISPR technology is a success
We’re delighted to report the successful completion of our research project in Dr Yung-Yao Lin’s laboratory at Queen Mary University of London. The …
Project that aimed to combine stem cell and CRISPR technology is a successRead More
Taking Raxone? We need your input!
The National Institute for Health and Care Excellence (NICE) is consulting on a potential new drug called Idebenone (or Raxone) which may slow …
Duchenne Science events back on the road in 2020
We've welcomed over 100 people to our Science on Tour events throughout 2019, these empowering and invaluable sessions have been a huge success and we …
